BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31:35-46. [PMID: 19785622 DOI: 10.1111/j.1365-2036.2009.04153.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Chen X, Xie Y, Sun Y, Wang X, Hesketh T. Irritable bowel syndrome and migraine: evidence from Mendelian randomization analysis in the UK Biobank. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34176420 DOI: 10.1080/17474124.2021.1949290] [Reference Citation Analysis]
2 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1:97-105. [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
3 Iturrino J, Camilleri M, Busciglio I, Burton D, Zinsmeister AR. Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults. Am J Physiol Gastrointest Liver Physiol 2011;301:G377-84. [PMID: 21596994 DOI: 10.1152/ajpgi.00085.2011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
4 Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303:G775-G785. [PMID: 22837345 DOI: 10.1152/ajpgi.00155.2012] [Cited by in Crossref: 204] [Cited by in F6Publishing: 194] [Article Influence: 22.7] [Reference Citation Analysis]
5 Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012;13:433-440. [PMID: 22251066 DOI: 10.1517/14656566.2012.651458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
6 Larauche M, Mulak A, Taché Y. Stress and visceral pain: from animal models to clinical therapies. Exp Neurol. 2012;233:49-67. [PMID: 21575632 DOI: 10.1016/j.expneurol.2011.04.020] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 13.0] [Reference Citation Analysis]
7 Rao S, Weber HC. New treatment targets for the management of irritable bowel syndrome. Current Opinion in Endocrinology, Diabetes & Obesity 2014;21:9-14. [DOI: 10.1097/med.0000000000000034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Blackshaw LA, Brierley SM. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol. 2013;7:15-19. [PMID: 23859756 DOI: 10.1586/17474124.2013.820045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
9 Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381-396. [PMID: 21090962 DOI: 10.1146/annurev-med-012309-103958] [Cited by in Crossref: 275] [Cited by in F6Publishing: 225] [Article Influence: 27.5] [Reference Citation Analysis]
10 Bian ZX, Qin HY, Tian SL, Qi SD. Combined effect of early life stress and acute stress on colonic sensory and motor responses through serotonin pathways: differences between proximal and distal colon in rats. Stress. 2011;14:448-458. [PMID: 21438781 DOI: 10.3109/10253890.2011.558604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
11 De Ponti F. Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol. 2013;4:7. [PMID: 23378837 DOI: 10.3389/fphar.2013.00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
12 Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med 2010;16:1248-57. [PMID: 20948530 DOI: 10.1038/nm.2235] [Cited by in Crossref: 408] [Cited by in F6Publishing: 335] [Article Influence: 37.1] [Reference Citation Analysis]
13 Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut 2010;59:1288-96. [PMID: 20801775 DOI: 10.1136/gut.2009.199653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
14 Voß U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol. 2012;473-497. [PMID: 23027463 DOI: 10.1007/978-3-642-30726-3_21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
15 Furness JB, Rivera LR, Cho HJ, Bravo DM, Callaghan B. The gut as a sensory organ. Nat Rev Gastroenterol Hepatol. 2013;10:729-740. [PMID: 24061204 DOI: 10.1038/nrgastro.2013.180] [Cited by in Crossref: 253] [Cited by in F6Publishing: 191] [Article Influence: 31.6] [Reference Citation Analysis]
16 Camilleri M. Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome. Clin Pharmacol Ther 2011;91:44-59. [DOI: 10.1038/clpt.2011.261] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
17 Wang FY, Su M, Zheng YQ, Wang XG, Kang N, Chen T, Zhu EL, Bian ZX, Tang XD. Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacol Sin 2015;36:708-15. [PMID: 25960135 DOI: 10.1038/aps.2014.170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
18 Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci. 2010;31:326-334. [PMID: 20554042 DOI: 10.1016/j.tips.2010.04.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
19 McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol 2016;7:414. [PMID: 27857691 DOI: 10.3389/fphar.2016.00414] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 13.6] [Reference Citation Analysis]
20 Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V. Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag 2015;11:691-703. [PMID: 26028974 DOI: 10.2147/TCRM.S54298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
21 Cada DJ, Levien TL, Baker DE. Linaclotide. Hosp Pharm 2013;48:143-52. [PMID: 24421452 DOI: 10.1310/hpj4802-143.test] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Yu Y, Daly DM, Adam IJ, Kitsanta P, Hill CJ, Wild J, Shorthouse A, Grundy D, Jiang W. Interplay between mast cells, enterochromaffin cells, and sensory signaling in the aging human bowel. Neurogastroenterol Motil 2016;28:1465-79. [PMID: 27206689 DOI: 10.1111/nmo.12842] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
23 Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20:14126-14131. [PMID: 25339801 DOI: 10.3748/wjg.v20.i39.14126] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
24 Bulmer DC, Grundy D. Achieving translation in models of visceral pain. Curr Opin Pharmacol. 2011;11:575-581. [PMID: 22000605 DOI: 10.1016/j.coph.2011.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
25 Iturrino J, Camilleri M, Busciglio I, Burton D, Zinsmeister AR. Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. Dig Liver Dis 2014;46:113-8. [PMID: 24095618 DOI: 10.1016/j.dld.2013.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Chen Y, Lin C, Tang Y, Chen AQ, Liu CY, Lu DL. ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats. World J Gastroenterol. 2014;20:2091-2097. [PMID: 24587682 DOI: 10.3748/wjg.v20.i8.2091] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
27 Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health. 2010;2:361-374. [PMID: 21151683 DOI: 10.2147/ijwh.s4537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
28 Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, Sacco S, Togha M; School of Advanced Studies of the European Headache Federation (EHF-SAS). Gut-brain Axis and migraine headache: a comprehensive review. J Headache Pain 2020;21:15. [PMID: 32054443 DOI: 10.1186/s10194-020-1078-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
29 Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011;23:193-200. [PMID: 21159063 DOI: 10.1111/j.1365-2982.2010.01643.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
30 Craig OF, Quigley EM. Current and emerging therapies for the management of functional gastrointestinal disorders. Ther Adv Chronic Dis 2011;2:87-99. [PMID: 23251744 DOI: 10.1177/2040622310389507] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
31 Pasricha PJ. Neurogastroenterology: A Great Career Choice for Aspiring Gastroenterologists Thinking About the Future. Gastroenterology 2011;140:1126-1128.e1. [DOI: 10.1053/j.gastro.2011.02.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Garbacz G, Kandzi A, Koziolek M, Mazgalski J, Weitschies W. Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions. AAPS PharmSciTech 2014;15:230-6. [PMID: 24297600 DOI: 10.1208/s12249-013-0050-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
33 Larauche M, Mulak A, Taché Y. Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. J Neurogastroenterol Motil. 2011;17:213-234. [PMID: 21860814 DOI: 10.5056/jnm.2011.17.3.213] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
34 Raschi E, De Ponti F. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2014;10:293-305. [PMID: 24387275 DOI: 10.1517/17425255.2013.876410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
35 Zhao JM, Chen L, Zhou CL, Shi Y, Li YW, Shang HX, Wu LY, Bao CH, Dou CZ, Wu HG. Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome. Evid Based Complement Alternat Med 2016;2016:9410505. [PMID: 27738447 DOI: 10.1155/2016/9410505] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Halland M, Talley NJ. New treatments for IBS. Nat Rev Gastroenterol Hepatol. 2013;10:13-23. [PMID: 23147658 DOI: 10.1038/nrgastro.2012.207] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
37 Manabe N, Rao AS, Wong BS, Camilleri M. Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. Curr Gastroenterol Rep 2010;12:408-16. [DOI: 10.1007/s11894-010-0124-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
38 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1:97-105. [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97.] [Reference Citation Analysis]